



市場行情
/
股票
/
nasdaq-bmy
/

Bristol-Myers Squibb Co

BMY

47.875USD

-0.814-1.67%

收盤 04/25, 16:00（美東）報價延遲15分鐘

96.04B總市值

虧損本益比TTM



Bristol-Myers Squibb Co

47.875

-0.814-1.67%

百時美施貴寶公司是一家生物製藥公司，致力於發現、開發和提供先進藥物，幫助患者戰勝嚴重疾病。該公司提供各種治療類別的產品，包括腫瘤學、血液學、免疫學、心血管和神經科學。其醫藥產品包括化學合成或小分子藥物、通過生物過程產生的產品（稱爲生物製劑）和嵌合抗原受體 (CAR-T) 細胞療法。小分子藥物通常以片劑或膠囊的形式口服，但也使用其他藥物輸送機制。生物製劑通過注射或靜脈輸液給患者給藥。其在線產品包括 Eliquis、Opdivo、Orencia、Pomalyst/Imnovid、Yervoy、Sprycel、Reblozyl、Opdualag、Abecma、Zeposia 等。該公司的產品線包括 Krazati、MRTX1719、RYZ101、KarXT、ORM-6151 和 Repotrectinib。

公司簡介

公司代碼BMY

公司名稱Bristol-Myers Squibb Co

上市日期Jul 05, 1929

成立日期1933

CEODr. Christopher S. (Chris) Boerner, Ph.D.

員工數量34100

證券類型Ordinary Share

年結日Jul 05

公司地址Route 206 And Province Line Road

城市PRINCETON

上市交易所NYSE Consolidated

國家United States of America

郵編08543

電話16092524621

網址https://www.bms.com

公司代碼BMY

上市日期Jul 05, 1929

成立日期1933

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

暫無數據

名稱

名稱/職務

職務

持股

持股變動

暫無數據

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.34%

Other

12.66B

26.22%

地區USD

名稱

營收

佔比

United States

34.10B

70.61%

International

13.20B

27.33%

other

996.00M

2.06%

業務

地區

業務USD

名稱

營收

佔比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.34%

Other

12.66B

26.22%

股東統計

更新時間: 4月26日週六

持股股東

股東類型

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

4.77%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.96%

Other

75.21%

持股股東

股東統計

佔比

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

4.77%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.96%

Other

75.21%

股東類型

股東統計

佔比

Investment Advisor

36.70%

Investment Advisor/Hedge Fund

32.55%

Research Firm

2.80%

Pension Fund

2.52%

Bank and Trust

2.26%

Sovereign Wealth Fund

1.84%

Hedge Fund

1.70%

Insurance Company

0.16%

Individual Investor

0.05%

Other

19.42%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

4166

1.65B

80.98%

+21.82M

2024Q4

4261

1.65B

81.14%

+17.04M

2024Q3

4116

1.60B

78.69%

-22.73M

2024Q2

4105

1.59B

78.35%

-83.12M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.39M

2023Q3

4042

1.63B

77.83%

-55.50M

2023Q2

4082

1.66B

78.77%

-34.93M

2023Q1

4110

1.66B

78.74%

-34.09M

2022Q4

4105

1.66B

77.92%

-72.60M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

189.02M

9.29%

+1.40M

+0.75%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.77%

-7.46M

-7.14%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.25M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.10M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.96%

-729.93K

-1.20%

Dec 31, 2024

Capital International Investors

45.87M

2.25%

+3.22M

+7.55%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.19M

+2.75%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.18M

1.73%

+2.58M

+7.92%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.50M

1.4%

+12.26M

+75.55%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.78%

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

First Trust NASDAQ Pharmaceuticals ETF

10.07%

VanEck Morningstar Wide Moat Value ETF

5.06%

Invesco Pharmaceuticals ETF

5.02%

Global X US Cash Flow Kings 100 ETF

4.97%

Invesco S&P Ultra Dividend Revenue ETF

4.9%

VictoryShares Free Cash Flow ETF

4.81%

VanEck Pharmaceutical ETF

4.81%

Cullen Enhanced Equity Income ETF

4.53%

Tema Oncology ETF

4.47%

iShares U.S. Pharmaceuticals ETF

4.38%

First Trust NASDAQ Pharmaceuticals ETF

佔比10.07%

VanEck Morningstar Wide Moat Value ETF

佔比5.06%

Invesco Pharmaceuticals ETF

佔比5.02%

Global X US Cash Flow Kings 100 ETF

佔比4.97%

Invesco S&P Ultra Dividend Revenue ETF

佔比4.9%

VictoryShares Free Cash Flow ETF

佔比4.81%

VanEck Pharmaceutical ETF

佔比4.81%

Cullen Enhanced Equity Income ETF

佔比4.53%

Tema Oncology ETF

佔比4.47%

iShares U.S. Pharmaceuticals ETF

佔比4.38%

分紅派息

近5年累計派現 22.71B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Bristol-Myers Squibb Co

47.875USD

Bristol-Myers Squibb Co

47.875

概覽

公司